Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine

Cifuentes, Francisco Tejada; Callejo, Ángeles Lloret; Peláez, María José; Pulido, Olga Rubio; Aragón, Marta Ruiz-Morote; Fernández-Urrusuno, Rocío; Carreras, María Isabel Muñoz; Esteban, María Isabel Méndez; Sánchez, Victoria Maestre; Bonilla, Antonio García; Dominguez, José Manuel Paredero; Pineda, Virginia Arroyo; Tejón, Esther Marco; Candel, G Romero; Marchante, Ana Isabel Fernández; Rio, José Marco del; Martín, Teresa Ortiz; Sánchez, Piedad López

doi:10.1016/j.medcle.2020.10.012

Cited by 3 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients under chronic use of HCQ have recorded lower SARS-CoV-2 infection rates compared to the general population [ 32 ]. However, recent studies evaluating the impact of chronic HCQ use on SARS-CoV-2 infection rates and hospitalization risk and its mortality-reducing effect found no significant evidence [ 30 , 33 , 34 , 35 ]. The excessive prescription of HCQ during the pandemic has ended, for which researchers cite the lack of evidence supporting the positive role of HCQ in COVID-19 as well as the associated risk of arrhythmias when used in combination with azithromycin [ 16 ].…”

Section: Epidemiology and Risk Factors For Covid-19mentioning

confidence: 99%

Pediatric Systemic Lupus Erythematous in COVID-19 Era

Lupu

Miron

Gavrilovici

et al. 2023

Viruses

View full text Add to dashboard Cite

Pediatric systemic lupus erythematosus is a chronic autoimmune disorder with a highly variable course and prognosis. It results in functional abnormalities in the immune system due to intrinsic factors and the use of immunosuppressive therapies associated with underlying comorbidities seem to increase the risk of severe COVID-19 and poor outcomes of the disease in pediatric systemic lupus erythematosus (SLE) patients. The aim of this review is to obtain a better understanding of the existing link between this new viral infection and pediatric lupus. We have analyzed the characteristics of newly diagnosed cases of pediatric SLE following COVID-19 which have been reported in the literature and which describe the impact that COVID-19 has on patients already suffering with pediatric SLE.

show abstract

Section: Epidemiology and Risk Factors For Covid-19mentioning

confidence: 99%

Pediatric Systemic Lupus Erythematous in COVID-19 Era

Lupu

Miron

Gavrilovici

et al. 2023

Viruses

View full text Add to dashboard Cite

show abstract

“…Therefore, it was suggested that the long-term HCQ treatment might protect against the infection [ 33 ]. On the contrary, no significant relationship was found between chronic use of HCQ and SARS-CoV-2 infection frequency in a cross-sectional multi-center study [ 34 ]. A population-based study evaluated the HCQ users for their SLE or rheumatoid arthritis, compared them with the general population, and found no evidence regarding the mortality-reducing effect of the HCQ prophylaxis [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

Asymptomatic SARS-CoV-2 seropositivity: patients with childhood-onset rheumatic diseases versus healthy children

et al. 2022

View full text Add to dashboard Cite

Objective We aimed to find out the asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence among pediatric patients with rheumatic diseases and healthy children and to compare them with each other. Methods Patients with familial Mediterranean fever (FMF), juvenile idiopathic arthritis (JIA), and juvenile systemic lupus erythematosus (jSLE) and healthy children as healthy control (HC) group who remained asymptomatic during the pandemic are examined by ELISA immunoglobulin (Ig) A and IgG tests in this cross-sectional study. Results Overall, 149 subjects (90 females) were included in the study. While IgA was positive in 15 subjects (10%) (HC: 8, jSLE: 3, FMF: 2, JIA: 2; p = 0.196), IgG was positive in 14 subjects (9.4%) (HC: 7, JIA: 5, FMF: 1, jSLE: 1; p = 0.156). Nineteen subjects (12.75%) were IgA or IgG positive (HC: 8, JIA: 5, jSLE: 3, FMF: 3; p = 0.644). Although not significant, seropositivity was more often in HC group. Both IgA and IgG positivity were not found to be related to age, sex, underlying rheumatic diseases, and received treatments of the patients. Conclusion We revealed that patients with childhood-onset rheumatic diseases, even if they receive immunosuppressive medication such as biologic or conventional disease-modifying anti-rheumatic drugs, might have an asymptomatic SARS-CoV-2 infection, similarly to their healthy peers. Key points • Although it has been already known that children are most likely to have asymptomatic SARS-CoV-2 infection, there is a lack of data on the disease course of children with rheumatic disease. • There was no significant difference regarding the asymptomatic SARS-CoV-2 seropositivity rates between healthy children and the patients with childhood-onset rheumatic diseases. • Patients with childhood-onset rheumatic diseases, even if they receive immunosuppressive medication, might have asymptomatic SARS-CoV-2 infection, similarly to their healthy peers.

show abstract

“…Hydroxychloroquine (HCQ) is utilized mainly in malaria and rheumatoid arthritis treatments [7]. Even though WHO does not recommend the hydroxychloroquine for preventing COVID-19, a previous study shows that the structure of hydroxychloroquine and its derivatives helps them to act against COVID-19 related pneumonia and also it is identified that the Covid-19 incidence does not appear to be related to chronic use of hydroxychloroquine [7]. Neutralizing antibodies have useful antiviral properties against the COVID-19.…”

Section: Fig3 Cell Entry Mechanism Of Coronavirusmentioning

confidence: 99%

“…It has been already illustrated that HCQ is suitable to be used against malaria and rheumatoid arthritis [7].…”

Section: Fig3 Cell Entry Mechanism Of Coronavirusmentioning

confidence: 99%

See 1 more Smart Citation

Quantum Chemical Studies on SARS-CoV-2-a Review

Yogeswari¹,

Venkatesh

Deivanayaki³

et al. 2022

2022 8th International Conference on Advanced Computing and Communication Systems (ICACCS)

View full text Add to dashboard Cite

On 11 th February 2020, World Health Organization (WHO) has recognized SARS-Cov-2 and announced it as an international community health emergency. On 30 th January 2020, it has been announced as a pandemic. Coronaviruses are large particles having unique surface projections and they are enveloped by many protein molecules like a cover including the spike glycoprotein (S-protein) [2] as shown in Fig. 1. The COVID-19 virus is RNA-pocketed through a strand. The S-protein of COVID-19 virus has a sugar coat of glycans which serves a challenge against the immunity of a human body (Fig. 2). The coronavirus is wrapped by large number of glycosylated S-proteins at its surface which helps them to attach with the host cell receptor Angiotensin Converting Enzyme 2 (ACE2). This mediates SARS-CoV-2 to go inside the human body.

show abstract

Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine

Cited by 3 publications

References 18 publications

Pediatric Systemic Lupus Erythematous in COVID-19 Era

Pediatric Systemic Lupus Erythematous in COVID-19 Era

Asymptomatic SARS-CoV-2 seropositivity: patients with childhood-onset rheumatic diseases versus healthy children

Quantum Chemical Studies on SARS-CoV-2-a Review

Contact Info

Product

Resources

About